Skip to main content

Evogene Ltd.

corporate_fare Company Profile

Evogene Ltd.

EVGN·NASDAQ·Industrial Applications And Services·CIK 0001574565

Evogene Ltd. is a computational biology company operating in Israel, the United States, Europe, and Africa. The company is structured into three segments: Agriculture, Human Health, and Industrial Applications. In its Agriculture segment, Evogene engages in activities related to seed traits and ag-chemicals. For Human Health, the company designs novel small molecules for drug development, utilizing its ChemPass AI, a computational generative AI engine. It also has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The Industrial Applications segment focuses on the development and commercialization of castor bean seeds for industrial uses. Additionally, the company is involved with medical cannabis products. Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.

Evogene Ltd. (NASDAQ:EVGN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 40 items for EVGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for EVGN spans 6-K, SCHEDULE 13D/A, 4, SCHEDULE 13D.

Recent high-impact activity:

  • Evogene Q3 Revenue Collapses to $141K After Bayer Deal Ends, Loss Widens
  • Evogene Chairman Nir Nimrodi Resigns Board Seat
  • Evogene and Activist Pure Capital Reach Deal to End Proxy Fight, Reconstitute Board
  • Evogene Secures 180-Day Nasdaq Extension to Regain $1 Bid Compliance
  • Evogene Reports H1 2026 Loss, Fully Utilizes ATM, and Faces Nasdaq Deadline and Dissident Tender Offer

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.85M
Net Income
-$7.83M
Diluted EPS
$1.08
Op. Cash Flow
-$13.5M
Free Cash Flow
-$13.64M
Gross Profit
-$241K
Operating Income
-$14.03M
Cash & Equivalents
$12.43M
Debt / Equity
0.00×
Net Margin
-203.1%
Shares Outstanding
8.72M sh
Source: 20-F · filed 2026-03-26 · accession 0001178913-26-001767

Short Interest & Short Volume

2.33 days to cover

FINRA reported short interest of 70,324 shares in EVGN as of the October 30, 2026 settlement, a 10.1% increase from the prior period — about 2.3 days to cover at its recent average daily volume. On November 20, 2026, 40.3% of EVGN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)70,324 shares as of October 30, 2026
Change vs prior period▲ 10.1%
Days to cover2.33 at avg daily volume of 30,149
Daily short volume (FINRA facilities)40.3% of 33,279 shares on November 20, 2026
5-day average short volume42.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for EVGN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-17.

2 recent capital raisesATM program

ATM Upsized to $3.3M · $1.75M Already Sold

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

EVGN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with E →
$0.313
52-week range · as of 2026-11-16 $0.2503 – $1.26
Market cap
$5.71M
Volume
62.8K (0.2× avg)
3-mo avg 415.4K
Live data · 2026-11-22 04:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EVGN - Latest Insights

EVGN
Nov 19, 2026, 7:12 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.3233
Real-time Price: $0.313 info
Change: -$0.0103 (-3%) info
Market Cap: $5.708M info
EVGN
Nov 16, 2026, 7:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3646
Real-time Price: $0.313 info
Change: -$0.0516 (-14%) info
Market Cap: $5.708M info
EVGN
Oct 06, 2026, 4:00 PM EDT
Source: PR Newswire
Importance Score:
9
Updated Oct 6, 4:08 PM ET — The cooperation agreement appoints Pure Capital nominees Dr. Adi Zuluf-Shani and Mr. Oz Adler to the board immediately, with Mr. Itay Maroz…
Price at Filing: $0.4101
Real-time Price: $0.313 info
Change: -$0.0971 (-24%) info
Market Cap: $5.708M info
EVGN
Sep 30, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4168
Real-time Price: $0.313 info
Change: -$0.1038 (-25%) info
Market Cap: $5.708M info
EVGN
Sep 28, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3907
Real-time Price: $0.313 info
Change: -$0.0777 (-20%) info
Market Cap: $5.708M info
EVGN
Sep 15, 2026, 5:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5281
Real-time Price: $0.313 info
Change: -$0.2151 (-41%) info
Market Cap: $5.708M info
EVGN
Sep 11, 2026, 6:31 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $0.4728
Real-time Price: $0.313 info
Change: -$0.1598 (-34%) info
Market Cap: $5.708M info
EVGN
Sep 04, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.569
Real-time Price: $0.313 info
Change: -$0.256 (-45%) info
Market Cap: $5.708M info
EVGN
Aug 18, 2026, 8:04 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.5596
Real-time Price: $0.313 info
Change: -$0.2466 (-44%) info
Market Cap: $5.708M info
EVGN
Aug 18, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.5999
Real-time Price: $0.313 info
Change: -$0.2869 (-48%) info
Market Cap: $5.708M info
EVGN
Aug 13, 2026, 2:39 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.6522
Real-time Price: $0.313 info
Change: -$0.3392 (-52%) info
Market Cap: $5.708M info
EVGN
Aug 13, 2026, 7:06 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.650
Real-time Price: $0.313 info
Change: -$0.337 (-52%) info
Market Cap: $5.708M info
EVGN
Aug 13, 2026, 7:00 AM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.598
Real-time Price: $0.313 info
Change: -$0.285 (-48%) info
Market Cap: $5.708M info
EVGN
Aug 11, 2026, 8:00 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $0.680
Real-time Price: $0.313 info
Change: -$0.367 (-54%) info
Market Cap: $5.708M info
EVGN
Aug 07, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.6123
Real-time Price: $0.313 info
Change: -$0.2993 (-49%) info
Market Cap: $5.708M info
EVGN
Jul 31, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.471
Real-time Price: $0.313 info
Change: -$0.158 (-34%) info
Market Cap: $5.708M info
EVGN
Jul 27, 2026, 7:22 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.5575
Real-time Price: $0.313 info
Change: -$0.2445 (-44%) info
Market Cap: $5.708M info
EVGN
Jul 22, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.525
Real-time Price: $0.313 info
Change: -$0.212 (-40%) info
Market Cap: $5.708M info
EVGN
Jul 20, 2026, 3:46 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.546
Real-time Price: $0.313 info
Change: -$0.233 (-43%) info
Market Cap: $5.708M info
EVGN
Jul 17, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.6208
Real-time Price: $0.313 info
Change: -$0.3078 (-50%) info
Market Cap: $5.708M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets